Noonan syndrome is a developmental disorder characterized by short stature, facial dysmorphia, congenital heart defects and skeletal anomalies 1 . Increased RAS-mitogen-activated protein kinase (MAPK) signaling due to PTPN11 and KRAS mutations causes 50% of cases of Noonan syndrome [2] [3] [4] [5] [6] . Here, we report that 22 of 129 individuals with Noonan syndrome without PTPN11 or KRAS mutation have missense mutations in SOS1, which encodes a RAS-specific guanine nucleotide exchange factor. SOS1 mutations cluster at codons encoding residues implicated in the maintenance of SOS1 in its autoinhibited form. In addition, ectopic expression of two Noonan syndrome-associated mutants induces enhanced RAS and ERK activation. The phenotype associated with SOS1 defects lies within the Noonan syndrome spectrum but is distinctive, with a high prevalence of ectodermal abnormalities but generally normal development and linear growth. Our findings implicate gain-of-function mutations in a RAS guanine nucleotide exchange factor in disease for the first time and define a new mechanism by which upregulation of the RAS pathway can profoundly change human development.
Noonan syndrome is an autosomal dominant, genetically heterogeneous trait. PTPN11, the first identified Noonan syndrome-associated gene 6 , encodes the nonmembranous protein tyrosine phosphatase SHP-2, which serves primarily positive regulatory roles in signal transduction, particularly via the receptor tyrosine kinase (RTK)-mediated RAS-MAPK pathway. Most mutations perturb the switch between the basally inactive and phosphotyrosine-bound active conformations of SHP-2, shifting the equilibrium towards the latter 3, [6] [7] [8] . LEOPARD syndrome, which resembles Noonan syndrome phenotypically, arises from a functionally distinct class of PTPN11 mutations 9, 10 . Recently, gain-of-function germline mutations have been found in HRAS in Costello syndrome and in KRAS in severe Noonan syndrome and cardiofaciocutaneous (CFC) syndrome 2, 4, 11, 12 . In addition, BRAF, MEK1 and MEK2 mutations have been observed in CFC 12, 13 . These disease gene discoveries have established Noonan syndrome and related traits as disorders of dysregulated RAS-MAPK signaling.
A crucial step in the activation of the RAS-MAPK pathway is the ligand-dependent conversion of RAS-GDP to RAS-GTP. In the context of RTK signaling, this reaction is catalyzed by the RAS-specific guanine nucleotide exchange factor (GEF) Son of Sevenless (SOS) 14 . Structural studies of SOS1, one of two human SOS proteins, have indicated that basally the protein is autoinhibited owing to complex regulatory intra-and intermolecular interactions [15] [16] [17] . After RTK stimulation, SOS1 is recruited to the plasma membrane, where it acquires a catalytically active conformation through an as-yet ill-defined mechanism.
To explore whether SOS1 mutations have a role in Noonan syndrome, we assembled genomic DNAs from 96 individuals without mutation in the established Noonan syndrome genes (cohort A) and performed high-throughput resequencing of the SOS1 coding region exons and flanking intronic boundaries. We identified 33 sequencing variants, including 12 nonsynonymous changes observed in 15 samples ( Table 1 and Supplementary Table 1 online) . Notably, three variants, affecting six subjects, altered Arg552, and a fourth affected Leu550. Both residues are evolutionarily conserved.
Among the seven variants from sporadic cases for which we possessed both parental samples, the relevant sequence change was not present in either parent in five; paternity was confirmed in each, providing final proof that these were de novo mutations ( Table 1) . For the two variants inherited from unaffected parents (P655L and H1320R) as well as two sporadic cases without parental samples (E433K and E846K) and three nonsynonymous variants cosegregating with disease in families with two to three affected individuals (W432R, L550P and Y702H), we identified only P655L in 155 control individuals. The H1320R change is probably a rare polymorphism, but we cannot exclude incomplete penetrance in the unaffected carrier. The remaining five variants were deemed disease-causing mutations. The prevalence of SOS1 mutations in the cohort was 13/ 96 or 12.5% (95% confidence interval (c.i.), 7.4%-22%), a lower limit owing to the incomplete coverage inherent with our highthroughput approach.
To further define the range of molecular defects, we scanned SOS1 in an additional 33 Noonan syndrome samples without PTPN11 or KRAS mutation (cohort B). This analysis uncovered nine subjects with SOS1 missense mutations as well as another probable rare nonsynonymous polymorphism, Q977R, inherited from an unaffected mother ( Table 1) .
In cohort B, we observed two additional mutations altering Arg552 and two independent S548R alleles, emphasizing the importance of that region. A second mutation cluster in the pleckstrin homology (PH) domain of SOS1 became apparent with the identification of an additional instance of E433K as well as a C441Y mutant. A third functional cluster residing in the interacting regions of the Dbl homology (DH) and RAS exchanger motif (Rem) domain was apparent with the identification of M269R, which joined W729L and I733F identified in cohort A.
Human SOS1 encodes a 150-kDa multidomain protein (Fig. 1a) . The GEF activity of SOS1 is controlled principally by two regulatory determinants: a catalytic site that forms a stable interaction with nucleotide-free RAS and an allosteric site that potentiates exchange activity through the binding of nucleotide-bound RAS 18 . Whereas the former is located entirely within the Cdc25 domain, the allosteric site is bracketed by the Cdc25 domain and Rem domains. Basally, the catalytic output of SOS1 is constrained by the DH-PH unit 15 , and structural data indicate that this autoinhibitory effect is exerted through DH-PH-mediated blockade of the allosteric site 17 . The three Noonan syndrome-associated SOS1 mutation clusters reside in regions within the molecule that are predicted to contribute structurally to the maintenance of the autoinhibition. Arg552 lies in the helical linker between the PH and Rem domains ( Fig. 1) and is predicted to interact directly with the side chains of Asp140 and Asp169 in the histone domain of SOS1 (ref. 16 ). Disruption of this interaction could affect the relative orientation of the DH-PH unit and the Rem domain. The mutation cluster represented by W432R, E433K and C441Y may disrupt the autoinhibited conformation by destabilizing the conformation of the DH domain. The third cluster (leading to the M269R, W729L and I733F alterations) affects residues that mediate the interaction of the DH and Rem domains. Trp729 interacts directly with Met269, thereby positioning the DH domain in its autoinhibitory conformation 17 .
To examine the functional consequences of Noonan syndromeassociated SOS1 mutations, we chose two representative SOS1 mutants, R552G and W729L, that were expressed transiently in Cos-1 cells. When we expressed wild-type SOS1, RAS activation was low in serum-deprived cells, increased rapidly after epithelial growth factor (EGF) stimulation and returned to near-basal levels by 30 min (Fig. 2a,b) . In contrast, expression of R552G SOS1 resulted in an increase in the basal level of active RAS and prolonged RAS activation after EGF stimulation. Expression of W729L resulted in essentially constitutive RAS activation. Next, we determined whether expression of these SOS1 mutants altered signal transduction through the MAPK ERK. In serum-deprived cells, R552G and W729L expression resulted in modest increases in pERK compared with the wild-type (Fig. 2c,d ). EGF-induced ERK activation did not differ among the SOS1 proteins (data not shown). The molecular basis of the differences between the extent of RAS activation and ERK activation for each SOS1 mutant is still not understood. These results confirmed our predictions that the Noonan syndrome-associated SOS1 mutations would principally abrogate autoinhibition, increasing RAS activation that would result in increased downstream signaling. Of note, Trp729 is involved in mediating the binding of RAS at the allosteric site 17 . Indeed, W729E substitution in SOS1 abrogates the binding of RAS-GTP to the allosteric site and reduces GEF activity 17 . The Noonan syndrome-associated W729L substitution is more conservative, and its gain-of-function effect is consistent with a preferential targeting of autoinhibition.
Extensive phenotype data were available for 16 individuals with SOS1 missense mutations. These individuals had cardiac disease (primarily pulmonary valve stenosis), pectus deformities, short and webbed neck and dysmorphic facial features ranging from those typical of Noonan syndrome to an appearance resembling CFC syndrome (Supplementary Table 1 and Supplementary Fig. 1  online) . Ectodermal features including facial keratosis pilaris and curly hair were significantly (P o 0.001) more prevalent among individuals with an SOS1 mutation compared with the general Noonan syndrome population. We observed height below the 3 rd centile in only 2 of 15 individuals with an SOS1 mutation, whereas prevalence is approximately 70% among individuals with Noonan syndrome in general and among affected individuals without a PTPN11 mutation. In contrast, macrocephaly was overrepresented among those with SOS1 mutations. Only one individual with an SOS1 mutation had mental retardation, potentially attributable to critical illness as a newborn. In comparison, 30% of all children with Noonan syndrome and 35% of those without a PTPN11 mutation require special education.
In our Noonan syndrome cohorts lacking PTPN11 and KRAS mutations, we identified SOS1 mutations in 17% of affected individuals. Just as for PTPN11, we found SOS1 mutations in sporadic and familial Noonan syndrome, and they engendered a high prevalence of pulmonary valve disease. The SOS1-associated phenotype, although clearly within the Noonan syndrome spectrum, resembled CFC in its dysmorphia, macrocephaly and ectodermal manifestations but differed notably in that it preserved development and linear growth. Among mutations causing developmental disorders with dysregulated RAS-MAPK signaling, SOS1 defects are notable for affecting a protein functioning upstream of RAS.
The results reported here represent the first examples of inherited gain-of-function mutations in SOS1. A frameshift mutation in exon 21 of SOS1 has been reported in one family inheriting the autosomal dominant trait hereditary gingival fibromatosis 19 . There have not been any other reports of SOS1 mutations in others with this trait, deferring proof of causality. Complete loss of Sos1 in mice is embryonic lethal owing to placental and cardiac defects, but haploinsufficient mice develop normally 20, 21 . Transgenic mice expressing a dominant active Sos1 in keratinocytes develop papillomata, which can be suppressed with reduced Egfr signaling 22 . In contrast to several other genes now associated with inherited disorders with dysregulated RAS signaling, somatic SOS1 mutations have not been reported in cancer. The biochemical analysis of two Noonan syndrome-related SOS1 proteins has uncovered gain-of-function effects resulting in increased RAS activation. As many of the target residues of the SOS1 mutations contribute to SOS autoinhibition by stabilizing either the interaction of the histone folds with the PH-Rem linker or the interaction of the DH domain with the Rem domain, the predominant pathogenetic mechanism seems to be a release of autoinhibition followed by an enhanced GEF activity and, as a consequence, increased RAS-GTP levels. GTP-bound RAS has been shown to interact with and activate multiple downstream effector pathways 23 . In addition, the DH-PH module of SOS has been implicated in the activation of the Rho GTPase Rac 24 . The extent to which SOS1 gain-of-function mutations effect different RAS-dependent or RAC-dependent signals remains to be determined.
The two highly conserved vertebrate SOS genes are widely expressed 25 . Sos1 and Sos2 bind a docking protein, Grb2, with different affinities 26 , and Sos2 cannot compensate for the loss of Sos1 in the Sos1 knockout mice, suggesting that these proteins have unique roles. We examined the hypothesis that SOS2 mutations similar to those in SOS1 can also cause Noonan syndrome but did not identify any sequence changes at homologous positions. With three disease genes identified for Noonan syndrome but 40% of cases unexplained, future efforts will be directed toward exploiting the candidate gene strategy in order to further advance diagnostics and prognostication for this disorder.
METHODS
High-throughput resequencing of SOS1. We assembled a cohort of 96 human subjects with Noonan syndrome and obtained genomic DNA from their peripheral blood leukocytes. Nearly all subjects were of European ancestry, with the majority being Italian. The subjects did not harbor PTPN11 or KRAS mutations, as determined by scanning the coding exons with DHPLC (Wave 2100 System, Transgenomic) and/or bidirectional DNA sequencing as previously described 2, 5 . For sporadic cases, which represented the vast majority of the subjects, we obtained both DNA from parents whenever possible. All nonanonymous samples were collected under Institutional Review Board-approved protocols with informed consent. Permission was obtained to publish the photographs of subjects shown in Supplementary Figure 1 online.
We chose a cohort of this size with the assumption that SOS1 would account for at least 1% of Noonan syndrome (or 2% of cases of Noonan syndrome lacking PTPN11 and KRAS mutations). Based on ref. 27 , this powered the study to detect a mutation in a Noonan syndrome gene at approximately 80% with a ¼ 0.05. If the gene accounted for 5% of cases of Noonan syndrome lacking PTPN11 and KRAS mutations, then the power to detect it with a cohort of this size would exceed 95%.
A high-throughput approach to the resequencing of SOS1 was performed at the Joint Genome Institute. The resequencing protocol was as follows: oligonucleotide primers (sequences available upon request) for amplifying the SOS1 coding exons (n ¼ 23) were designed to give a product size in the range of 200-700 bp with a minimum of 40 bp flanking the splice sites using the Exon Primer program, which is bundled with the UCSC Genome Browser (build hg17). M13F and M13R tags were added to the forward and reverse primers, respectively. Five nanograms of genomic DNA from each Noonan syndrome sample were amplified in an 8-ml PCR reaction using AmpliTaq Gold (Applied Biosystems) on PE 9700 machines and were subsequently cleaned using a diluted version of the Exo-SAP based PCR product pre-sequencing kit (USB Corporation) dispensed by a nanoliter dispenser (Deerac Fluidics Equator). All PCR set-up procedures were performed in a 384-well format using a Biomek NX workstation after optimization. Sequencing reactions were then performed using the M13 primers along with BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and cleaned with BET before separation on an ABI 3730xl DNA Analyzer. Base calling, quality assessment and assembly were carried out using the Phred, Phrap, Polyphred, Consed software suite. All sequence variants identified were verified by manual inspection of the chromatograms, and putative causative mutations were verified using another independent sequencing reaction.
Analysis of the second Noonan syndrome cohort, controls and paternity. We assembled a second panel of 33 Noonan syndrome genomic DNAs lacking PTPN11 and KRAS mutations. This panel was used as to confirm the results of the first panel and to extend the range of mutations associated with Noonan syndrome. These DNAs were scanned for SOS1 mutations using DHPLC analysis of PCR-generated amplimers at column temperatures recommended by the Navigator version 1.5.4.23 software (oligonucleotide primer sequences and DHPLC conditions available upon request). Amplimers having abnormal denaturing profiles were purified (Microcon PCR, Millipore) and sequenced bidirectionally using the ABI BigDye terminator Sequencing Kit v.1.1 (Applied Biosystems) and an ABI Prism 310 Genetic Analyzer (Applied Biosystems). When available, parental DNA was sequenced to establish whether the identified changes were de novo. Paternity was confirmed by simple tandem repeat (STR) genotyping using the AmpF/STR Identifier PCR Amplification Kit (Applied Biosystems). Anonymous control genomic DNAs from persons of European ancestry were screened for SOS1 coding exons in which putative mutations had been identified using DHPLC and abnormal amplimers were sequenced bidirectionally as described above. Eighty-five additional control DNA samples from persons of European ancestry were digested with MneI (New England Biolabs) or BsrsI (Promega) to further exclude occurrence of the 1297G-A and 1649T-C missense changes, respectively.
Genotype-phenotype analysis was performed, comparing the prevalence of features in individuals with Noonan syndrome and SOS1 mutations to that in all individuals with Noonan syndrome 28 and those without PTPN11 mutation 5 . Statistical testing was performed with w 2 analysis, using a threshold of P o 0.05 as significant.
RAS activation assay. GST-RAF-RAS binding domain fusion proteins were expressed in Escherichia coli by induction with 0.5 mM of isopropyl-1-thiob-D-galactopyranoside (IPTG) for 5 h. The expressed fusion proteins were isolated from bacterial lysates by affinity chromatography with glutathione agarose beads for 1 h at 4 1C. Cos-1 cells were cotransfected with hemagglutinintagged wild-type HRAS and wild-type or mutant SOS1. We switched cells 24 h after transfection to serum-starvation medium (0% DMEM) for 16 h. After stimulation with EGF (10 ng/ml) for the indicated intervals at 37 1C, the cells were collected in RBD lysis buffer containing 25 mM Tris-HCl (pH 7.4), 120 mM NaCl, 10 mM MgCl 2 , 1 mM EDTA, 10% glycerol, 10 mg/ml pepstatin, 50 mM NaF, 1% aprotinin, 10 mg/ml leupeptin, 1 mM Na 3 VO 4 , 10 mM benzamidine, 10 mg/ml soybean trypsin inhibitor, 1% NP-40, 0.25% sodium deoxycholic acid. For each condition, 400 mg of whole-cell lysate was precleared with 10 ml 50% GST for 5 min at 4 1C. The samples were then centrifuged and supernatants were transferred to Eppendorf tubes containing 20 mg GST-RAF-RBD immobilized beads. Samples were incubated for 1.5 h at 4 1C. The complexes were collected by centrifugation and washed six times with buffer containing 25 mM Tris-HCl (pH 7.4), 120 mM NaCl, 10 mM MgCl 2 , 1 mM EDTA, 10% glycerol, 50 mM NaF and 1% NP-40. Protein complexes were eluted with SDS sample buffer, separated by 12.5% SDS-PAGE and transferred to a nitrocellulose membrane. The proteins were detected by protein blot with anti-hemagglutinin (12CA5; 1:10,000) and goat anti-mouse HRP conjugated secondary antibody (Cappel; 1:10,000).
ERK activation assay. Cos-1 cells were transfected with expression vectors encoding HA-ERK2 and HA-tagged SOS1 constructs. After 24 h of expression, cells were serum starved for 16 h and lysed in immunoprecipitation buffer (1% (vol/vol) Triton X-100, 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10% (vol/vol) glycerol) supplemented with protease inhibitors. Lysates were subjected to immunoprecipitation with monoclonal anti-hemagglutinin (12CA5) and subsequently incubated with a 1:1 protein A slurry. Beads were washed three times with immunoprecipitation buffer and resuspended in an SDS sample buffer. Samples were run on SDS-PAGE and then transferred to nitrocellulose membranes. Membranes were probed by anti-hemagglutinin or anti-ERK2 (Upstate Biotechnology) and anti-pERK (Cell Signaling). Relative ERK phosphorylation ratios were quantified using the Odyssey software and were normalized to total ERK expression.
URLs. Exon Primer: http://ihg.gsf.de/ihg/ExonPrimer.html; UCSC Genome Browser: http://genome.ucsc.edu/. Informatics analysis of sequences to predict splice acceptor and donor sites as well as exonic splice enhancers was performed using programs available at the following websites: http://www.cbs.dtu.dk/ services/NetGene2, http://www.fruitfly.org/seq_tools/splice.htmland http:// rulai.cshl.edu/tools/ESE. Phred, Phrap, Polyphred, Consed software suite: http://www.phrap.org/.
